Results 171 to 180 of about 1,181,836 (211)

A Review of CT-P13: An Infliximab Biosimilar

BioDrugs, 2014
CT-P13 (Remsima™; Inflectra™), a biosimilar of reference infliximab (Remicade(®)), is approved by the European Medicines Agency for use in all indications for which reference infliximab is approved, including rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriatic arthritis and psoriasis.
openaire   +2 more sources

Ineffectiveness of infliximab CT‐P13 for the treatment of scleromyxedema: A case report

Dermatologic Therapy, 2017
a
Arginelli, Federica, Paganelli, Alessia, Rongioletti, Franco, Pellacani, Giovanni, Conti, Andrea   +4 more
openaire   +2 more sources

CT-P13 in the treatment of rheumatoid arthritis

Expert Review of Clinical Immunology, 2017
The first biosimilar infliximab, CT-P13 infliximab-dyyb was approved in 2013 by the European Medicines Agency (EMA) and in 2016 by the United States Food and Drug Administration (FDA) and has been used for the treatment of rheumatoid arthritis (RA) for 4 years.
openaire   +2 more sources

Switch from biosimilar infliximab CT-P13 to biosimilar infliximab SB-2 in the long-term maintenance therapy in IBD patients – prospective observational study

Gastroenterology & hepatology, 2023
Introduction: Therapeutical switch from originator to biosimilar infliximab has been proved as effective and safety procedure. We have a few information about non-medical swich from one biosimilar to the another biosimilar infiximab.
Milan Lukas, Veronika Hrubá, Jindra Reissigová, K. Černá, N. Machková, D. Ďuricová, M. Kolář, Lea Čermáková   +7 more
semanticscholar   +1 more source

CT-P13: a review on a biosimilar to infliximab in the treatment of inflammatory bowel disease

Expert Opinion on Biological Therapy, 2019
Introduction: CT-P13 was developed as an infliximab biosimilar in 2013. The primary structure of CT-P13 is identical to that of original infliximab and it has highly similar higher order structure, physiochemical characteristics, and biological properties.
Ahmad Albshesh, Shomron Ben-Horin
openaire   +2 more sources

P1142 Time to clinical recapture after dose escalation of subcutaneous infliximab (CT-P13 SC) following loss of response: A post hoc analysis of the 2-year Phase 3 LIBERTY-CD & LIBERTY-UC trials

Journal of Crohn's & Colitis
Subcutaneous (SC) infliximab (IFX) is approved for the treatment of Crohn’s disease (CD) and ulcerative colitis (UC) at a dose of 120 mg every other week (EOW).1 While the effectiveness of dose escalation (DE) to 240 mg EOW has been suggested,2,3 ...
M. Dubinsky, S. Schreiber, A. Yarur, B. Sands, S. Hanauer, S. Danese, H. Yu, D. H. Kim, Y. N. Lee, J. Colombel   +9 more
semanticscholar   +1 more source

TWO-YEAR RESULTS OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) DOSE ESCALATION THERAPY - FROM LIBERTY-CD AND LIBERTY-UC

Gastroenterology
Dose escalation (DE) of subcutaneous (SC) infliximab from 120 mg to 240 mg every 2 weeks (Q2W) showed restoring efficacy in the 54-week LIBERTY-CD and LIBERTY-UC studies, and safety profiles were generally comparable between patients with or ...
Stephen B. Hanauer, S. Danese, J. Colombel, W. Sandborn, B. Sands, S. Schreiber, SangJoon Lee, Sunghyun Kim, Yunju Bae, Sunhee Lee, Seulgi Lee, J. Lee, Jongmin Kim, G. Park, Jimin Lee, Chaeyoung Kim   +15 more
semanticscholar   +1 more source

Drug survival of the infliximab biosimilar (CT-P13) in paediatric patients with non-infectious uveitis

Clinical and Experimental Rheumatology, 2021
Paediatric non-infectious uveitis (NIU) is an important cause of significant long-term complications and blindness in children. Infliximab (IFX) is a chimeric human/murine monoclonal antibody against TNF-α that is effective in NIU resistant to conventional therapies.
Betül, Sözeri, Esra, Kardeş, Enes, Salı, Deniz, Çakır, Ferhat, Demir   +4 more
openaire   +2 more sources

P1064 Association of subcutaneous infliximab CT-P13 serum levels and therapeutic outcomes in patients affected by Inflammatory Bowel Disease: A retrospective international multicentric study

Journal of Crohn's & Colitis
The association between therapeutic outcomes and serum levels associated with the use of subcutaneous (SC) IFX CT-P13 in patients with inflammatory bowel disease [IBD] has been poorly studied.
A. Centritto, M. Samaan, M. Ward, J. V. van Wees, A. Outtier, M. Ferrante, G. Novak, Ž. Šubic, K. Papamichail, P. Irving   +9 more
semanticscholar   +1 more source

A real-world, observational, prospective cohort study evaluating the safety and effectiveness of CT-P13 in inflammatory bowel disease and rheumatoid arthritis: the MEGA-J study

Current Medical Research and Opinion
Objective The primary objective of the MEGA-J study (UMIN-CTR number: UMIN000057308) was to assess the safety of CT-P13, an infliximab biosimilar, in Japanese patients with Crohn’s disease (CD), ulcerative colitis (UC), and/or rheumatoid arthritis (RA ...
T. Ishida, I. Yokoe, Hirozumi Obata, Soyeon Park, SooKyoung Kim, N. Nishimata   +5 more
semanticscholar   +1 more source